In the BioHarmony Drug Report Database
Selinexor
Xpovio, Nexpovio (selinexor) is a small molecule pharmaceutical. Selinexor was first approved as Xpovio on 2019-07-03. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target exportin-1. Xpovio’s patents are valid until 2035-08-14 (FDA).
Trade Name
|
Nexpovio |
|---|---|
Common Name
|
selinexor |
ChEMBL ID
|
CHEMBL3545185 |
Indication
|
multiple myeloma |
Drug Class
|
Exportin 1 inhibitors |
Image (chem structure or protein)